A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
NCT04814108
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
92
Enrollment
INDUSTRY
Sponsor class
Conditions
Uterine Serous Carcinoma
Interventions
DRUG:
Azenosertib
Sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc